StreetAlpha.app
Home › Stocks › VERU

Veru Inc. (VERU)

Healthcare
$2.14
▲ +2.88%
LAST CLOSE · NOV 17

Veru is a Miami-based drug developer working on enobosarm for obesity and sabizabulin for inflammatory heart disease. It last closed at $2.14 on Nov 17, up 2.88% on the day. VERU reports earnings on Thu, Nov 26, 2026.

AI Auto Pilots
Is VERU in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$13.6M
EPS (diluted)
−$0.58
Free cash flow
−$26.0M
Valuation
Market cap
$36.5M
17.1M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$23.9M
At Jun 30
Shareholder equity
$28.4M
Shares outstanding
17.1M
At Aug 6
Fiscal year endsSeptember
ExchangeNasdaq
Financials history
FY2021: $61.3M$61.3MFY2021FY2022: $39.4M$39.4MFY2022FY2023: $16.3M$16.3MFY2023FY2024: $16.9M$16.9MFY2024

From VERU's SEC filings, latest 10-Q for the period ending Jun 30, 2026 (filed Aug 10). Last 12 months adds up the four latest quarters.

Next report
Nov 26
2026 · Time not announced
Consensus EPS forecast
-$0.25
 
Year-ago EPS
—
Not on file
Options-implied move
—
Posted about a week before
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated VERU in the past 90 days, not enough for a consensus
Average 12-month target
$28.00
▲ 1208.4% upside

Based on 1 analyst who set a price target on VERU in the past 90 days. The average target is $28.00, with a high of $28.00 and a low of $28.00, compared with the last close of $2.14.

Low $28.00Avg $28.00High $28.00
Blue marker: last close $2.14
Highest target$28.00
Average target$28.00
Lowest target$28.00
Latest rating changes
WestPark CapitalInitiated
Oct 6Buy$28
Canaccord GenuityMaintained
Jun 4Buy$25
DateFirmActionRatingPrice target
Oct 6WestPark CapitalInitiatedBuy$28
Jun 4Canaccord GenuityMaintainedBuy$25
Loading…

Technical Analysis

VERU · as of the Nov 17 close · updated after every close
Downtrend

The stock is 2% below its 20 day and 9% below its 50 day average. It is 15% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 44). The nearest support is the Pivot at $2.13, and the nearest resistance the 20 day average at $2.18.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityNormal, 5.1%/day
Key levels
$7.3352 week high+242.5%
$2.47200 day average+15.4%
$2.46100 day average+15.0%
$2.3350 day average+8.9%
$2.21Swing high (Nov 9)+3.3%
$2.19Pivot R1+2.3%
$2.1820 day average+1.9%
$2.14Last close
$2.13Pivot−0.5%
$2.11Swing low (Jun 4)−1.4%
$2.08Pivot S1−2.8%
$2.0352 week low−5.1%
Indicators
RSI (14)44.20Middle of its rangeNeutral
MACD-0.07Below its signal lineBearish
Stochastic21.9Middle of its rangeNeutral
ADX (14)11.3No clear trend
Williams %R-63.3Oversold below −80, overbought above −20Neutral
CCI (20)-54.7Oversold below −100, overbought above 100Neutral
Rate of change−0.9%Change over 10 sessionsBearish
ATR (14)$0.11Typical daily range, 5.1% of price
MA 10Above
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for VERU

What happened before

See how VERU did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Earnings in 8 daysSignals right before a report are less reliable. The report can override them.
November seasonalityHow VERU usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How VERU has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in VERU in the last 90 days.

Loading…

See today’s whale options flow across the market →

VERU Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼15 buying vs 27 selling
  • ▼Held by funds -2.5 pts
  • ▼Funds holding -6
  • ●Superinvestors: 1 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding5561−9.8%
In funds' top 1000–
Held by funds15.3%17.8%−2.5 pts
New / increased6 / 912 / 13−40.0%
Reduced / sold out15 / 1214 / 10+12.5%
Put/call ratio–0.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See VERU institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether VERU is in one of them and how their past VERU trades turned out.

VERU in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered VERU in an article yet. Here's the latest on the wider market.

About Veru

Veru is a drug development company based in Miami, Florida. Its lead candidate, enobosarm, is an oral medicine designed for patients with obesity who take GLP-1 drugs, with the aim of helping them keep muscle while losing fat. Its second candidate, sabizabulin, is being studied as a treatment for inflammation in atherosclerotic cardiovascular disease, a condition in which fatty deposits build up in the arteries. The company's candidates are aimed at patients with these conditions and the doctors who treat them.

Headquarters
Miami, FL